fbpx

What Is Relapsed vs. Refractory Myeloma?

There are so many myeloma phrases, terminology and acronyms that things can get incredibly confusing. Let's talk about Relapsed Myeloma (sort of self explanatory) and Refractory Myeloma (need a refresher course on this one!). Relapsed Myeloma  According to Dr. Sagar Lonial, MD of the Winship Cancer Institute at Emory University, Relapsed Myeloma "specifically includes patients [...]

Read More

CLINICAL TRIAL: New Immunotherapy (Reovirus called Reolysin) Now Being Used for Relapsed/Refractory Myeloma with Bortezomib + Dex

A new immunotherapy called a reovirus is being used in combination with standard myeloma drugs in an early clinical trial. This reovirus helps boost tumor-fighting activities and has been studied with both allogeneic and autologous transplant. Researchers are now combining this reovirus, called Reolysin, with other standard myeloma drugs without transplant. Last December, results from [...]

Read More

Full Show: Not Giving Up on Treatment Options for Relapsed/Refractory Myeloma Patients with Dr. David Siegel, MD, PhD, John Theurer Cancer Center

Thanks to our episode sponsor Dr. David Siegel, MD, PhD John Theurer Cancer Center Interview Date: April 15, 2016 Summary If multiple myeloma patients relapse or become refractory to existing medications, it doesn't mean the disease has won. Dr. David Siegel explains the difference between "relapsed" and "refractory" and shares a hopeful message [...]

Read More

How & When To Treat Relapsed Multiple Myeloma

When deciding on the optimal treatment for an individual with relapsed multiple myeloma, it is important to determine whether the relapse was biochemical in nature and whether the patient has standard-risk or high-risk disease, comments Noopur Suresh Raje, MD. An individual with high-risk disease is more likely to encounter poorer outcomes, such as organ dysfunction, [...]

Read More

More About Ixazomib for Relapsed/Refractory Multiple Myeloma: What Is It & How You Can Get It

Takeda Pharmaceutical Company announced that the U.S. FDA has granted Priority Review status for ixazomib, the first investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma. “We are encouraged that both the U.S. and European regulatory bodies have determined that the ixazomib applications qualify for an expedited review, underscoring [...]

Read More

Panobinostat + Velcade & Dex Improves Progression Free Survival For Myeloma Patients With At Least 2 Prior Therapies

BY SILAS INMAN for OncLive The addition of panobinostat (Farydak) to bortezomib (Velcade) and dexamethasone improved progression-free survival (PFS) by 7.8 months in a subgroup of 147 patients with multiple myeloma who had received at least 2 prior treatments, including bortezomib and an immunomodulatory agent (IMiD), in the phase III PANORAMA-1 trial. In the subanalysis, [...]

Read More

Elotuzumab Plus Older Treatments Delays Myeloma Progression In Relapsed Patients, Says Study

BY BILL BERKROT for REUTERS The addition of an experimental Bristol-Myers Squibb biotech medicine to standard therapy for patients whose multiple myeloma has relapsed led to longer remissions and cut the risk of death over standard treatment alone, according to data from a late stage study. The drug, elotuzumab, which is being developed in collaboration with [...]

Read More

Triple Drug Combinations Show Positive Results For Treating Myeloma, Including For Relapsed Disease

OncLive interviews Dr. Sundar Jagannath, MD, Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute. He discusses the latest treatments for relapsed myeloma patients, three-drug combos, and the role natural killer cells and immunotherapy plays in the future of treatments.  Three-Drug Combos, Immunotherapy Mark Future of Myeloma [...]

Read More

Wall Street Journal: Amgen’s Multiple Myeloma Drug Meets Endpoint in Trial

From The Wall Street Journal Amgen's Multiple Myeloma Drug Meets Endpoint in Trial By Joshua Jamerson Aug. 4, 2014 8:25 a.m. ET Amgen (AMGN) said its multiple myeloma Kyprolis drug met its primary endpoint in an interim analysis, showing progression-free survival for patients treated with relapsed multiple myeloma. Kyprolis, in combination with two other drugs, [...]

Read More

Bendamustine, Thalidomide and Dex: Viable Salvage Option for Double-Relapsed/Refractory Myeloma Patients

Bendamustine plus thalidomide and dexamethasone may be a viable salvage option for the treatment of patients with double-relapsed/refractory multiple myeloma, a recent study published in the journal Annals of Hematology has shown. For the study, researchers retrospectively analyzed data from 30 patients with double-relapsed/refractory multiple myeloma who received bendamustine, thalidomide, and dexamethasone in 28-day cycles. Patients received [...]

Read More

Clinical Trial Update: Expanding Treatment Options For Relapsed/Refractory Myeloma Patients

According to Targeted Oncology, the treatment options for patients with relapsed/refractory multiple myeloma are expanding rapidly, notably through clinical trial evidence supporting a number of three-drug combination regimens. Sundar Jagannath, MD, the director of the Multiple Myeloma Program at The Tisch Cancer Institute and a professor at Mount Sinai School of Medicine in New York [...]

Read More

Early Myeloma Diagnosis And Proper Treatment Impacts Outcomes

For those diagnosed with multiple myeloma, selecting the proper treatment has a big impact on outcomes. But before proper treatment options can be identified, it is critical to know as much about the patient's specific disease first. Better testing is helping determine best options by the individual patient, as opposed to the once "one size fits all" approach. Over [...]

Read More

Study Shows Combo Of Carfilzomib, Lenalidomide & Dex Promising For Relapsed Myeloma Patients

According to results published in the Dec. 6 New England Journal of Medicine, relapsed multiple myeloma patients who were treated with carfilzomib, in addition to lenalidomide and dexamethasone, had improved progression-free survival.  Lenalidomide in combination with high-dose dexamethasone is approved for use in relapsed multiple myeloma on the basis of phase 3 trials showing superiority to dexamethasone alone, [...]

Read More

ASH Notes: Treating The Relapsed Myeloma Patient

Attending my first ASH conference is an amazing experience. New treatments and therapies, clinical trials, results of drug combinations… it’s quite the whirlwind. One topic I’m particularly interested in is how relapsed patients are treated. This morning, Dr. Joseph Mikhael of Mayo Clinic in Arizona presented on that very topic. Here are the key things I [...]

Read More

Get Started Today.

Find a Clinical Trial that's Right for You

Go

Thanks to our site sponsors: